Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 with RFA for Unresectable Cholangiocarcinoma
NCT02592538Completed
- Sponsor
- Hangzhou First People's Hospital
- Start
- Dec 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tegafur in cholangiocarcinoma (CCA) (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Survival Time at 2 years. Started Dec 2015; status: completed.
02
Drugs
tegafur
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02592538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592538.